How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 3, 2010, Pages 308-314

  Li, Xiang Yang ^a   Chang, Ju Ping ^a   Su, Zhuo Wa ^a   Li, Jiu Hong ^a   Peng, Bo Shen ^a   Zhu, Sheng Lang ^a   Cai, An Ji ^a   Zhang, Jun ^a   Jiang, Ying ^a  

^a The 6th Affiliated Hospital of Shenzhen University Health Science Center   (China)

Author keywords

C reactive protein; Hemodialysis; Hepcidin; Interleukin 6; Prohepcidin; Simvastatin

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRITIN; HEMOGLOBIN; HEPCIDIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID PLUS SIMVASTATIN; POLYSULFONE; PROHEPCIDIN; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN; ANTIMICROBIAL CATIONIC PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN PRECURSOR;

ADULT; AGED; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; IRON BALANCE; IRON DEFICIENCY; IRON TRANSPORT; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; YOUNG ADULT;

ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HEPCIDINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEIN PRECURSORS; RENAL DIALYSIS; SIMVASTATIN; YOUNG ADULT;

EID: 77952895437     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00783.x     Document Type: Article

References (35)

1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001 37 (Suppl 1 S-182 283.
2. Locatelli F, Aljama P, Barany P et al. European Best Practice Guidelines Working Group: revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004 19 (Suppl 2 S-1 47.
3. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 2002 17 (Suppl 11 28 31. Review.
4. Stenvinkel P, Bárány P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002 17 (Suppl 5 S-32 7. Review.
5. Winkels DW, Wetzels JF. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 2008 23 : 2450 2453.
6. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001 276 : 7806 7810.
7. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004 306 : 2090 2093.
8. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002 110 : 1037 1044.
9. De Domenico I, Ward DM, Langelier C et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007 18 : 2569 2578.
10. Darshan D, Anderson GJ. Interacting signals in the control of hepcidin expression. Biometals 2009 22 : 77 87.
11. Tomosugi N, Kawabata H, Wakatabe R et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006 108 : 1381 1387.
12. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008 112 : 4292 4297.
13. Ashby DR, Gale DP, Busbridge M et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009 75 : 976 981.
14. Kulaksiz H, Gehrke SG, Janetzko A et al. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004 53 : 617 619.
15. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004 42 : 387 389.
16. Eleftheriadis T, Kartsios C, Liakopoulos V et al. Does hepcidin affect erythropoiesis in hemodialysis patients?. Acta Haematol 2006 116 : 238 244.
17. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006 107 : 2702 2704.
18. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004 43 : 471 478.
19. Sezer MT, Katirci S, Demir M, Erturk J, Adana S, Kaya S. Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients. Scand J Urol Nephrol 2007 41 : 436 441.
20. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005 68 : 237 245. (Pubitemid 43181381)
21. Arabul M, Gullulu M, Yilmaz Y et al. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem 2008 41 : 1055 1058.
22. Panichi V, Paoletti S, Mantuano E et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006 21 : 337 344.
23. Mantuano E, Santi S, Filippi C et al. Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomed Pharmacother 2007 61 : 360 365.
24. Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 2003 14 : 329 334.
25. Liang YJ, Shyu KG, Wang BW, Lai LP. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Cardiology 2008 110 : 182 190.
26. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003 101 : 2461 2463.
27. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008 180 : 6988 6996.
28. Lee SJ, Qin H, Benveniste EN. Simvastatin inhibits IFN-gamma-induced CD40 gene expression by suppressing STAT-1alpha. J Leukoc Biol 2007 82 : 436 447.
29. Dummer CD, Thome' FS, Zingano B, Lindoso A, Veronese FV. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. J Nephrol 2008 21 : 900 908.
30. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003 16 : 238 244.
31. Zoller H, McFarlane I, Theurl I et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology 2005 42 : 466 472.
32. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005 106 : 1864 1866.
33. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 2008 40 : 132 138.
34. Hadley KB, Johnson LK, Hunt JR. Iron absorption by healthy women is not associated with either serum or urinary prohepcidin. Am J Clin Nutr 2006 84 : 150 155.
35. Hilgendorff A, Muth H, Parviz B et al. Statins differ in their ability to block NF-κB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003 41 : 397 401.